Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Biotechnology

Healthcare
$37.75 -0.55%

-$0.29 today

Market cap
$3.71B
Beta
0.63
P/E (TTM)
-12.1
EPS (TTM)
-$4.39
52W Low $30.00High $63.95

Volume 1.30M

Average 1.16M

XENE Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Xenon Pharmaceuticals Inc.NASDAQ: XENE

Revenue · Q3 FY2026 · quarter ended Sep 2026

Revenue remains negative

Q3 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0. Over 3 fiscal years it compounded at -7.4% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 7 analysts of $1.44M (-80.8%) for the fiscal year ending Dec 2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$7.5M— YoY
LTMSep 2026
$0-100.0% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year—-80.8%—
3-year CAGR-7.4%+204.4%+211.7 pp
5-year CAGR+166.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
7.5M USD
Year-over-year change
—
4-year CAGR
-20.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How XENE compares with its peers on the latest reported figures

  • XENE's LTM Sep 2026 revenue of $0 is the 8th highest of the 11 companies compared; the peer median is $398.28M.
  • Its year-over-year change of -100.0% is the 6th highest of 7, against a peer median of +19.8%.
  • Over three fiscal years its annual growth of -7.4% compares with a peer median of +24.3%.
XENE Competitors Peer median
Revenue for XENE and competitors
Company Period LTM YoY 3-year CAGR
JAZZJazz Pharmaceuticals plcLTM Sep 2026$4.72B +13.5%+5.3%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$3.7B +38.0%+24.3%
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$1.2B +14.8%+27.5%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$830.44M +24.9%+2.5%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$776.57M +56.9%+133.7%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$20M ——
DNLIDenali Therapeutics Inc.LTM Jun 2026$3.6M ——
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$0 -100.0%-7.4%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$0 -100.0%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$0 ——
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$0 ——
Peer median (excluding XENE) $398.28M+19.8%+24.3%

Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.44M9.43M007.5M
Cost of Revenue00167.51M2.56M2.54M
Gross Profit18.44M9.43M(167.51M)(2.56M)4.96M
Gross Margin100.0%100.0%——66.1%
Research & Development75.46M105.77M167.51M210.39M300.94M
Selling, General & Admin21.97M32.81M46.54M68.9M79.63M
Operating Expenses97.43M138.58M46.54M276.74M378.03M
Depreciation & Amortization906K1.41M3.54M2.56M2.54M
EBITDA(78.09M)(127.74M)(210.51M)(235.86M)(342.35M)
EBITDA Margin-423.5%-1354.0%——-4564.7%
Operating Income(78.99M)(129.14M)(214.05M)(279.3M)(373.07M)
Operating Margin-428.4%-1368.9%——-4974.3%
Interest Income466K8.71M27.62M41.94M26.83M
Interest Expense00000
Other Income / Expenses105K3.89M31.37M40.88M28.18M
Income Before Tax(78.89M)(125.26M)(182.69M)(238.42M)(344.89M)
Pre-Tax Margin-427.9%-1327.7%——-4598.6%
Income Tax Expense(6K)118K(292K)(4.09M)1.02M
Net Income(78.88M)(125.37M)(182.39M)(234.33M)(345.91M)
Net Margin-427.8%-1328.9%——-4612.1%
EPS (Basic)(1.77)(2.06)(2.73)(3.01)(4.36)
EPS (Diluted)(1.77)(2.06)(2.73)(3.01)(4.36)
Weighted Avg Shares43.63M60.54M66.89M77.89M79.25M
Weighted Avg Shares (Diluted)43.63M60.54M66.89M77.89M79.25M

Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Intrinsic Alpha fair value

Locked

Current Price

$37.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.